Literature DB >> 2739924

The lesion of multiple sclerosis: imaging of acute and chronic stages.

R A Koopmans1, D K Li, J J Oger, J Mayo, D W Paty.   

Abstract

Increased blood-brain barrier (BBB) permeability, important in the pathogenesis of MS, may be demonstrated as lesion enhancement with high-volume delayed CT (HVDCT). We studied 40 MS patients with history, neurologic examination, HVDCT, and MRI. In addition, 7 of the patients with enhancing CT lesions were followed with serial MRI for up to 3 years and 7 months. In 3 of these patients we repeated the HVDCT. Patients with enhancing lesions on CT were younger, had shorter duration of disease, and had more frequent clinical relapses than did patients without enhancement. More than half (56%) of the enhancing CT lesions were in the deep white matter, 23% were periventricular, and 21% were at the gray/white matter junction. Half the CT enhancing lesions, when followed by serial MRI, showed significant changes in lesion size. Although the majority (59%) of these lesions faded, some remained actively changing (25%) or became confluent with adjacent lesions (16%). In 48% of the MRI examinations that showed activity, some lesions were increasing in size while others were simultaneously decreasing in size. This study confirms that MS is a dynamic process in which recurrent episodes of BBB disruption and inflammation play a major role. Recurrent episodes of inflammation may well be a prelude to the largely irreversible changes of demyelination and gliosis.

Entities:  

Mesh:

Year:  1989        PMID: 2739924     DOI: 10.1212/wnl.39.7.959

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

Review 1.  Statins as potential therapeutic agents in multiple sclerosis.

Authors:  Olaf Stüve; Thomas Prod'homme; Sawsan Youssef; Shannon Dunn; Oliver Neuhaus; Martin Weber; Hans-Peter Hartung; Lawrence Steinman; Scott S Zamvil
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

2.  Multiple sclerosis masquerading as a mass lesion.

Authors:  D W Giang; K R Poduri; T A Eskin; L M Ketonen; P A Friedman; D D Wang; R M Herndon
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

3.  Characterizing contrast-enhancing and re-enhancing lesions in multiple sclerosis.

Authors:  Z Campbell; D Sahm; K Donohue; J Jamison; M Davis; C Pellicano; S Auh; J Ohayon; J A Frank; N Richert; F Bagnato
Journal:  Neurology       Date:  2012-04-25       Impact factor: 9.910

Review 4.  Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials.

Authors:  J H Simon
Journal:  West J Med       Date:  1996-06

5.  MRI in subacute combined degeneration.

Authors:  S Murata; H Naritomi; T Sawada
Journal:  Neuroradiology       Date:  1994-07       Impact factor: 2.804

6.  Metabolically dependent blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis.

Authors:  C P Hawkins; P M Munro; D N Landon; W I McDonald
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

7.  Pattern recognition in magnetic resonance imaging of white matter disorders in children and young adults.

Authors:  M S van der Knaap; J Valk; N de Neeling; J J Nauta
Journal:  Neuroradiology       Date:  1991       Impact factor: 2.804

8.  Imaging of human T-lymphotropic virus type I-associated chronic progressive myeloneuropathies.

Authors:  F Alcindor; R Valderrama; M Canavaggio; H Lee; A Katz; C Montesinos; R E Madrid; R R Merino; P A Pipia
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

9.  In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis.

Authors:  M K Sharief; R Hentges; M Ciardi; E J Thompson
Journal:  J Neurol       Date:  1993-01       Impact factor: 4.849

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.